Becotatug Vedotin联合Pucotenlimab治疗铂类及免疫治疗耐药复发/转移性鼻咽癌
Magic-C001研究评估EGFR导向抗体偶联药物BV联合PD-1抑制剂pucotenlimab在铂类及抗PD-1/PD-L1治疗失败的复发/转移性鼻咽癌患者中的疗效与安全性。在31例接受II期推荐剂量治疗的患者中,确认的客观缓解率为71.0%,疾病控制率93.5%,中位缓解持续时间14.0个月,中位无进展生存期12.0个月,≥3级治疗相关不良事件发生率为40.6%。
要点
- BV联合pucotenlimab在铂类及免疫治疗耐药鼻咽癌中显示高缓解率与持久缓解。
- 确认ORR达71.0%,DCR 93.5%,中位PFS 12.0个月。
- 毒性可管理,≥3级TRAE发生率40.6%,无治疗相关死亡。
核心结论
- BV联合pucotenlimab在铂类及抗PD-1/PD-L1耐药的复发/转移性鼻咽癌中产生显著客观缓解、持久缓解和明显延长的无进展生存期,毒性可管理。
研究设计与样本
- Magic-C001(NCT05688605)为正在进行的开放标签、多队列、剂量递增(I期)和扩展(II期)研究,纳入EGFR阳性实体瘤患者。
- 鼻咽癌患者接受pucotenlimab 3.0 mg/kg联合BV 2.0 mg/kg(II期推荐剂量),每3周一次。
- 分析集为I期和II期中接受II期推荐剂量、既往接受过抗PD-1/PD-L1及铂类治疗的31例鼻咽癌患者。
- II期主要终点为客观缓解率,次要终点包括缓解持续时间、疾病控制率、无进展生存期、总生存期和安全性。
主要发现
- 确认的ORR为71.0%(95% CI 52.0–85.8),DCR为93.5%(95% CI 78.6–99.2)。
- 中位DoR为14.0个月(95% CI 5.7–未估计),中位PFS为12.0个月(95% CI 6.8–15.4)。
- 中位OS尚未成熟。
- 最常见TRAE为瘙痒(71.9%)、感觉减退(65.6%)、贫血(59.4%)和皮疹(56.3%)。
- ≥3级TRAE发生率为40.6%,无TRAE导致死亡。
临床怎么用
- 该方案可能为铂类及抗PD-1/PD-L1耐药的复发/转移性鼻咽癌患者提供有前景的抗PD-1再挑战策略。
- 该联合方案的疗效正在一项正在进行的多中心随机对照III期研究中确认。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti-PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combined with a PD-1 inhibitor pucotenlimab in this setting of patients. MATERIALS AND METHODS: Magic-C001 (ClinicalTrials.gov identifier: NCT05688605) is an ongoing, open-label, multicohort, dose escalation (phase I) and expansion (phase II) study in patients with EGFR-positive solid tumors. Eligible patients received pucotenlimab 3.0 mg/kg and BV at 1.8-2.3 mg/kg (phase I) or 2.0 mg/kg (phase II for NPC) once every 3 weeks. The primary end point for phase II was objective response rate (ORR). Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Among 31 patients with NPC at the recommended phase II dose (RP2D) from phase I and II who had received anti-PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0 to 85.8); DCR was 93.5% (95% CI, 78.6 to 99.2). The median DoR and PFS were 14.0 months (95% CI, 5.7 to not estimated) and 12.0 months (95% CI, 6.8 to 15.4), respectively. Median OS was not mature. Most common treatment-related adverse events (TRAEs) were pruritus (71.9%), hypoesthesia (65.6%), anemia (59.4%), and rash (56.3%). TRAEs of ≥grade 3 occurred in 40.6% of patients. No TRAEs led to death. CONCLUSION: To our knowledge, we report the first trial combining an ADC with immunotherapy for platinum and anti-PD-1/PD-L1-resistant NPC. BV plus pucotenlimab yielded a notable ORR with exceptionally durable responses and substantially prolonged PFS, alongside manageable toxicities. This regimen may offer a promising anti-PD-1 rechallenge strategy in this population, which is being confirmed in an ongoing, multicenter, randomized controlled, phase III study.
引用
- Ruan DY, Wang FH, Zhou Y, et al. Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma. J Clin Oncol. 2026. PMID: 42641116. doi:10.1200/JCO-26-00640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。